NCT04887805View on ClinicalTrials.gov

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 21, 2021

Primary Completion Date

November 5, 2026

Study Completion Date

November 5, 2026

Conditions
Advanced Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Lenvatinib Mesylate

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER